[The P phenomenon in ulcerative colitis].
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000503:physiopathology; D003093:Colitis, Ulcerative / Q000276:immunology / Q000503:physiopathology*; D003106:Colon; D003920:Diabetes Mellitus / Q000276:immunology / Q000503:physiopathology; D005260:Female; D006801:Humans; D007106:Immune Sera / Q000494:pharmacology; D007583:Jejunum; D007962:Leukocytes; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000503:physiopathology; D008297:Male; D008638:Mesenteric Arteries / Q000187:drug effects; D051381:Rats; D014020:Tissue Extracts / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000494:pharmacology / Q000502:physiology*; D005719:gamma-Globulins
D007106:Immune Sera; D014020:Tissue Extracts; D014662:Vasoconstrictor Agents; D005719:gamma-Globulins
Das P-Phänomen bei Colitis ulcerosa.